共 151 条
[1]
Boguszewski CL(2016)Management of endocrine disease: acromegaly and cancer: an old debate revisited Eur J Endocrinol 175 R147-R156
[2]
Ayuk J(2009)Acromegaly pathogenesis and treatment J Clin Invest 119 3189-3202
[3]
Melmed S(2008)Does acromegaly enhance mortality? Rev Endocr Metab Disord 9 33-39
[4]
Ayuk J(2014)Acromegaly: an endocrine society clinical practice guideline J Clin Endocrinol Metab 99 3933-3951
[5]
Sheppard MC(2009)The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration BMJ 339 b2700-250
[6]
Katznelson L(2013)Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force Value Health 16 231-178
[7]
Laws ER(2015)Conducting systematic reviews of economic evaluations Int J Evid Based Healthc 13 170-A227
[8]
Melmed S(2008)Economic evaluation of long term somatostatin analogs in the treatment of acromegaly in Mexico Value Health 11 A227-1460
[9]
Molitch ME(2008)Cost-effectiveness analysis of somatostatin analogues in the treatment of acromegaly in Brazil Arquivos brasileiros de endocrinologia e metabologia 52 1452-234
[10]
Murad MH(2009)Cost-effectiveness of lanreotide Autogel in treatment algorithms of acromegaly Expert Rev Pharmacoecon Outcomes Res 9 223-106